Les informations fournies sur EL7.AI sont uniquement à des fins éducatives et informatives et ne constituent pas un conseil financier.
Les informations fournies sur EL7.AI sont uniquement à des fins éducatives et informatives et ne constituent pas un conseil financier.
On March 15, OrbiMed Advisors increased its stake in RAPT Therapeutics by 556,273 shares during the fourth quarter. RAPT Therapeutics was acquired for $58 per share. Prior to the acquisition, OrbiMed's stake in the company was valued at approximately $56 million.